Hancom (CEO Seong-jun Byun and Yeon-soo Kim) plans to make a strategic investment in FacePhi, a Spanish artificial intelligence (AI) biometric company. Hancom announced on the 25th that it has signed an investment agreement in Barcelona, Spain, with Hancom's CEO Yeon-soo Kim and FacePhi's CEO Javier Mira in attendance. This investment agreement will allow Hancom to make equity investments in FacePhi and secure exclusive business rights to FacePhi in the APAC region. Listed simultaneously on the Spanish and French stock ...Leggi tutta la notizia su liberoquotidiano
Hancom announces strategic investment in Spanish AI biometric company FacePhi - BARCELONA and SEOUL, South Korea, March 25, 2024 /PRNewswire/ -- Hancom (CEO Seong-jun Byun and Yeon-soo Kim) plans to make a strategic investment in FacePhi, a Spanish artificial intelligence (AI) ...adnkronos
First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent - Telix Pharmaceuticals Limited today announces that the first patient has been dosed in its named patient program in Italy for TLX250-CDx (89Zr-DFO-girentuximab, Zircaixtm[1]). TLX250-CDx is the ...lelezard
ONO PHARMA announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL - ONO Pharmaceuticals, Co., Ltd. today announced it has completed target patient enrollment of the first arm (Part A) of the PROSPECT Study, a Phase 2 clinical trial evaluating the safety and efficacy ...lelezard
Facebook
Tik Tok
Twitter
Instagram
You Tube
